Allarity Therapeutics shares are trading higher after the company collaborated with FivepHusion to support clinical development of Deflexifol with DRP companion diagnostics.
Portfolio Pulse from Benzinga Newsdesk
Allarity Therapeutics has partnered with FivepHusion to support the clinical development of Deflexifol with DRP companion diagnostics. This collaboration has led to a rise in Allarity's share prices.
July 31, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allarity Therapeutics' stock is trading higher after the company announced its collaboration with FivepHusion for the clinical development of Deflexifol.
The collaboration with FivepHusion for the clinical development of Deflexifol is a positive development for Allarity Therapeutics. This partnership could potentially lead to advancements in their product offerings, which is likely the reason behind the increase in their stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100